Combination of Gas Plasma and Radiotherapy Has Immunostimulatory Potential and Additive Toxicity in Murine Melanoma Cells in Vitro.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
18 Feb 2020
Historique:
received: 20 01 2020
revised: 15 02 2020
accepted: 17 02 2020
entrez: 23 2 2020
pubmed: 23 2 2020
medline: 1 12 2020
Statut: epublish

Résumé

Despite continuous advances in therapy, malignant melanoma is still among the deadliest types of cancer. At the same time, owing to its high plasticity and immunogenicity, melanoma is regarded as a model tumor entity when testing new treatment approaches. Cold physical plasma is a novel anticancer tool that utilizes a plethora of reactive oxygen species (ROS) being deposited on the target cells and tissues. To test whether plasma treatment would enhance the toxicity of an established antitumor therapy, ionizing radiation, we combined both physical treatment modalities targeting B16F10 murine melanoma cell in vitro. Repeated rather than single radiotherapy, in combination with gas plasma-introduced ROS, induced apoptosis and cell cycle arrest in an additive fashion. In tendency, gas plasma treatment sensitized the cells to subsequent radiotherapy rather than the other way around. This was concomitant with increased levels of TNFα, IL6, and GM-CSF in supernatants. Murine JAWS dendritic cells cultured in these supernatants showed an increased expression of cell surface activation markers, such as MHCII and CD83. For PD-L1 and PD-L2, increased expression was observed. Our results are the first to suggest an additive therapeutic effect of gas plasma and radiotherapy, and translational tumor models are needed to develop this concept further.

Identifiants

pubmed: 32085661
pii: ijms21041379
doi: 10.3390/ijms21041379
pmc: PMC7073141
pii:
doi:

Substances chimiques

Immunologic Factors 0
Plasma Gases 0
Reactive Oxygen Species 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Bundesministerium für Bildung und Forschung
ID : 03Z22DN11
Organisme : European Social Fund
ID : ESF/14-BM-A55-0006/18

Déclaration de conflit d'intérêts

The authors declare no conflict of interest with regard to the publication of this manuscript.

Références

Int J Cancer. 2008 Sep 15;123(6):1448-56
pubmed: 18567001
PLoS One. 2016 Sep 01;11(9):e0160667
pubmed: 27584003
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
Oncoimmunology. 2013 Oct 1;2(10):e26536
pubmed: 24404424
Immunol Res. 2011 Dec;51(2-3):170-82
pubmed: 22139852
Strahlenther Onkol. 2018 Jun;194(6):509-519
pubmed: 29500551
Cancer Res. 2013 Oct 15;73(20):6106-10
pubmed: 24097822
Front Immunol. 2015 Aug 07;6:402
pubmed: 26300886
Adv Sci (Weinh). 2019 Jan 28;6(6):1802062
pubmed: 30937272
Environ Mol Mutagen. 2018 May;59(4):268-277
pubmed: 29417643
Cancer Lett. 2015 Jan 1;356(1):105-13
pubmed: 24139966
Sci Rep. 2017 Jun 5;7(1):2791
pubmed: 28584285
Cancer Immunol Immunother. 2016 Jul;65(7):779-86
pubmed: 26590829
Nat Rev Dis Primers. 2019 Feb 21;5(1):13
pubmed: 30792503
Oncogene. 2003 May 19;22(20):3188-92
pubmed: 12789295
Mutat Res Genet Toxicol Environ Mutagen. 2016 Mar;798-799:48-54
pubmed: 26994493
Nat Rev Cancer. 2009 May;9(5):371-7
pubmed: 19360021
Cancer Immunol Immunother. 2012 Feb;61(2):215-221
pubmed: 22193987
J Inflamm (Lond). 2010 Jul 27;7:37
pubmed: 20663192
Oral Oncol. 2019 Jul;94:93-100
pubmed: 31178219
Cell Cycle. 2010 Feb 15;9(4):662-9
pubmed: 20139725
Cytometry A. 2016 Jul;89(7):653-62
pubmed: 27272602
In Vivo. 2019 Jul-Aug;33(4):1011-1026
pubmed: 31280189
Front Oncol. 2012 Oct 26;2:153
pubmed: 23112958
J Thorac Oncol. 2017 Jul;12(7):1085-1097
pubmed: 28478231
Sci Rep. 2018 Aug 24;8(1):12734
pubmed: 30143716
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
Sci Rep. 2018 May 16;8(1):7689
pubmed: 29769707
Mol Cell Biol. 2009 May;29(10):2828-40
pubmed: 19273588
Cell Death Dis. 2014 Feb 13;5:e1056
pubmed: 24525732
Curr Opin Immunol. 1998 Oct;10(5):573-80
pubmed: 9794839
Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):313-322
pubmed: 30776401
Oncol Rep. 2007 May;17(5):1183-8
pubmed: 17390063
Oncotarget. 2016 Apr 19;7(16):21469-83
pubmed: 26894978
Semin Cell Dev Biol. 2018 Aug;80:50-64
pubmed: 28587975
Oxid Med Cell Longev. 2019 Sep 19;2019:8535163
pubmed: 31641425
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Arch Biochem Biophys. 2016 Sep 1;605:19-25
pubmed: 27085689
Oxid Med Cell Longev. 2019 Oct 8;2019:9062098
pubmed: 31687089
Nature. 2015 Nov 12;527(7577):186-91
pubmed: 26466563
Oxid Med Cell Longev. 2017;2017:4396467
pubmed: 28761621
Int J Hyperthermia. 2016;32(1):23-30
pubmed: 26754406
PLoS One. 2012;7(8):e40690
pubmed: 22912665
Antioxid Redox Signal. 2014 Mar 1;20(7):1086-97
pubmed: 23373831
Bioessays. 2013 Jul;35(7):623-31
pubmed: 23666891
J Phys D Appl Phys. 2019 Oct 22;52(42):
pubmed: 31485083
Cytokine. 2017 Sep;97:123-132
pubmed: 28648866
Methods Mol Biol. 2019;1904:83-108
pubmed: 30539467
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
Sci Rep. 2019 Jan 24;9(1):634
pubmed: 30679720
Exp Dermatol. 2016 Jul;25(7):497-500
pubmed: 27060971
Front Oncol. 2016 Jun 20;6:141
pubmed: 27379203
Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):986-97
pubmed: 24661650
Clin Transl Radiat Oncol. 2017 Feb 04;2:29-35
pubmed: 29657997
Sci Rep. 2012;2:636
pubmed: 22957140
Cancer Lett. 2015 Oct 28;367(2):103-7
pubmed: 26188281

Auteurs

Gabriella Pasqual-Melo (G)

ZIK plasmatis, Leibniz Institute for Plasma Science and Technology, Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany.

Sanjeev Kumar Sagwal (SK)

ZIK plasmatis, Leibniz Institute for Plasma Science and Technology, Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany.

Eric Freund (E)

ZIK plasmatis, Leibniz Institute for Plasma Science and Technology, Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany.
Department of General, Visceral, Thoracic and Vascular Surgery, Greifswald University Medical Center, Ferdinand-Sauerbruch-Str., 17475 Greifswald, Germany.

Rajesh Kumar Gandhirajan (RK)

ZIK plasmatis, Leibniz Institute for Plasma Science and Technology, Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany.

Benjamin Frey (B)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Maximiliansplatz 2, 910524 Erlangen, Germany.

Thomas von Woedtke (T)

ZIK plasmatis, Leibniz Institute for Plasma Science and Technology, Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany.
Institute for Hygiene and Environmental Medicine, Greifswald University Medical Center, Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany.

Udo Gaipl (U)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Maximiliansplatz 2, 910524 Erlangen, Germany.

Sander Bekeschus (S)

ZIK plasmatis, Leibniz Institute for Plasma Science and Technology, Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH